<?xml version="1.0" encoding="UTF-8"?>
<table-wrap position="float" id="tbl1">
 <label>Table 1</label>
 <caption>
  <p>The Vaccine Development Stages and the Process.</p>
 </caption>
 <alt-text id="alttext0025">Table 1</alt-text>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th>Phase</th>
    <th>Aim</th>
    <th>Features</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td>Exploratory</td>
    <td>
     <bold>
      <italic>Develop a vaccine.</italic>
     </bold>
    </td>
    <td>Research intensive phase.
     <break/>Identify synthetic or natural antigen.
     <break/>Develop a vaccine (natural or synthetic).
     <break/>Time: 2-5 years. 
     <sup>μ</sup>
     <break/>The success rate to proceed is 40%. 
     <sup>δ</sup>
     <break/>Causes of failure based on the nature of the pathogen.
    </td>
   </tr>
   <tr>
    <td>Preclinical</td>
    <td>
     <bold>
      <italic>The vaccine is safe and immunogenic.</italic>
     </bold>
     <break/>
     <bold>
      <italic>Evaluate the starting dose for human studies.</italic>
     </bold>
    </td>
    <td>Subjects: Vaccine is studied in Cell culture &amp; animals.
     <break/>Design: toxicity and antibody response, challenge studies.
     <break/>Time: &lt;1 year.
     <break/>The success to proceed is 33%. 
     <sup>δ</sup>
     <break/>Causes of a failure-vaccine toxic or ineffective immune response, underfunding.
    </td>
   </tr>
   <tr>
    <td>Clinical Trial Authorization</td>
    <td>
     <bold>
      <italic>Allow human experiments (Application for IND)</italic>
     </bold>
    </td>
    <td>The basis for authorization-Manufacturing steps &amp; analytical methods for vaccine &amp; placebo production,
     <break/>Availability and stability of vaccine &amp; placebo during clinical studies.
     <break/>Time: within 30 days.
    </td>
   </tr>
   <tr>
    <td>Phase I
     <sup>α</sup>
    </td>
    <td>
     <bold>
      <italic>First-in-human testing. Vaccine safety and immune response.</italic>
     </bold>
    </td>
    <td>Subjects: Healthy volunteers (20 -100).
     <break/>Site: vicinity of the tertiary care for close observation.
     <break/>Design: Escalation study to avoid severe adverse effects (SAE).
     <break/>Monitor: Health outcomes (clinical and laboratory) and antibody production
     <break/>Time: a few mon.
     <break/>Success rate to proceed 66 %. 
     <sup>δ</sup>
     <break/>Caution: Follow strict go/no-go criteria based on safety and immunity data
    </td>
   </tr>
   <tr>
    <td>Phase II
     <sup>α</sup>
     <sup>€</sup>
    </td>
    <td>
     <bold>
      <italic>Vaccine safety, immunity/partial efficacy.</italic>
     </bold>
     <break/>
     <bold>
      <italic>Dose-response, schedule &amp; method of delivery</italic>
     </bold>
    </td>
    <td>Subjects: Healthy volunteers (hundreds), may include a diverse set of humans.
     <break/>Site: Community-based (university, colleges, schools, etc).
     <break/>Study design: studied against a placebo, adjuvant, or established vaccine.
     <break/>Dose: Test vaccine in different schedules and a diverse set of humans.
     <break/>Monitor: Health outcomes (clinical and laboratory) and antibody response
     <break/>Partial efficacy data can be procured under circumstances.
     <break/>Time: 2yr.
     <break/>Success rate to proceed 30 %. 
     <sup>δ</sup>
    </td>
   </tr>
   <tr>
    <td>Phase III
     <sup>α</sup>
    </td>
    <td>
     <bold>
      <italic>Vaccine efficacy and safety</italic>
     </bold>
     <sup>
      <bold>
       <italic>≠</italic>
      </bold>
     </sup>
    </td>
    <td>Subjects: Target population (thousands).
     <break/>Site: Field conditions similar to future vaccine use.
     <break/>Design: vaccine randomized vis-a-vis a placebo, adjuvant, or an established vaccine.
     <break/>Monitor: Vaccine Efficacy and SAE.
     <break/>Time: many years.
     <break/>Success rate to proceed 70 %. 
     <sup>δ</sup>
    </td>
   </tr>
   <tr>
    <td>Biologic License Application</td>
    <td>
     <bold>
      <italic>Marketing of vaccine</italic>
     </bold>
     <sup>
      <bold>
       <italic>£</italic>
      </bold>
     </sup>
    </td>
    <td>The basis for approval-The vaccine is safe and effective in humans (Efficacy &gt;95%).
     <break/>Capacity to produce in bulk for market demand.
     <break/>Affordable cost to a susceptible population.
    </td>
   </tr>
   <tr>
    <td>Phase IV</td>
    <td>
     <bold>
      <italic>Postmarketting surveillance</italic>
     </bold>
    </td>
    <td>Spontaneous reporting (Adverse Events Reporting System).
     <break/>Monitor: data collected by the end-users.
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn id="tspara0015">
   <p>≠=Vaccine Efficacy (VE)=(Iu-Iv/Iu) x100= (1-Iv/Iu) x100= (1-RR) X100 %. (Iv=incidence in vaccine group, Iu=incidence in unvaccinated group, RR=relative risk).</p>
  </fn>
  <fn id="tspara0020">
   <p>μ=Platform Technology has shortened time for vaccine production from years to days.</p>
  </fn>
  <fn id="tspara0025">
   <p>α=Clinical trials are rate-limiting in vaccine marketing.</p>
  </fn>
  <fn id="tspara0030">
   <p>€=Human challenge studies can be done in phase IIa in certain diseases where the challenge is ethical.</p>
  </fn>
  <fn id="tspara0035">
   <p>€=Phase IIb studies can provide data on efficacy in regions with a high prevalence of the disease in the community.</p>
  </fn>
  <fn id="tspara0040">
   <p>£=The cost of developing a vaccine from research and discovery to product registration is around US$ 1 Billion.</p>
  </fn>
  <fn id="tspara0045">
   <p>This figure includes vaccines that are abandoned during the development process.</p>
  </fn>
  <fn id="tspara0050">
   <p>δ=The overall success rate for vaccine development is around 15%.</p>
  </fn>
 </table-wrap-foot>
</table-wrap>
